anumigilimab   Click here for help

GtoPdb Ligand ID: 11761

Synonyms: CSL-324 | CSL324
Compound class: Antibody
Comment: Anumigilimab (CSL-324) is a clinical stage monoclonal antibody that targets colony stimulating factor 3 receptor (CSF3R). It was developed by CSL Behring for potential efficacy in inflammatory/autoimmune diseases. The heavy and light chain peptide sequences for anumigilimab are claimed in patent WO2012171057A1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Anumigilimab (CSL-324) is in early stage clinical development. Study NCT04519424 to determine anumigilimab's ability to reduce inflammation in patients with severe COVID-19 was withdrawn (for business reasons), before any patients were recruited.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03972280 Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Phase 1 Interventional CSL Behring
NCT04570267 Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects Phase 1 Interventional CSL Behring